In acute pain, IA increases – acting like a natural sedative for the pain pathways – but in chronic pain, this current ...

A new study reveals that when we experience short-term (acute) pain, the brain has a built-in way to dial down pain signals - like pressing the brakes - to keep them from going into overdrive.

“Today’s approval is an important public health milestone in acute pain management,” Jacqueline Corrigan-Curay, ... The Best Cartoons on Donald Trump. July 2, 2025, at 2:50 p.m. Photos: ...

People with acute pain, he said, could simply take 400 milligrams of ibuprofen and 1,000 milligrams of acetaminophen, a “non-opioid combo that we believe is more effective” than Journavx.

A recent study published in the Journal of Orthopaedic Research pinpointed the three best medications for acute lower back pain, characterized as pain lasting 12 weeks or less.

A new painkiller that is said to be free of addiction risks may be transformative for treatment of acute pain, according to local medical professionals. “I think it could be a potentially ...

INNOVATOR Q&A New app is looking to understand your pain At Brown University’s brain institute, a group of neuroscientists developed SOMA, a new mobile app that tracks acute and chronic pain ...

Professor Christine Lin says the evidence shows opioids do not help acute neck and back pain. (Supplied: Stefanie Zingsheim/University of Sydney)The researchers recruited almost 350 people who ...

Studies in more than 870 patients with acute pain due to foot and abdominal surgeries showed Vertex’s drug provided more relief than a dummy pill but didn’t outperform a common opioid ...

An experimental pain medicine met the primary goal of a late-stage clinical trial, the drugmaker said Tuesday, setting the stage for it to seek approval from the US Food and Drug Administration ...

The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with acute pain. The FDA has approved the non-opioid, highly selective ...

Acute and subacute pain improvement: At the end of the 12-week study, Hinge Health participants reported a 73% pain reduction and a 2x lower pain score compared to nonparticipants.